Vanta Bioscience Ltd
BSE:540729
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Amara Raja Energy & Mobility Ltd
NSE:ARE&M
|
IN |
|
I
|
Isetan (Singapore) Ltd
SGX:I15
|
SG |
|
B
|
Brightek Optoelectronic Co Ltd
TWSE:5244
|
TW |
|
I
|
International Gas Product Shipping JSC
VN:GSP
|
VN |
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IN |
|
Vanta Bioscience Ltd
BSE:540729
|
129.6m INR |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
194.1B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
137B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
36.6B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
318.8B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
33.4B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
31.3B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
29.2B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.3B USD |
Loading...
|
Market Distribution
| Min | -3 052.3% |
| 30th Percentile | 26.9% |
| Median | 39% |
| 70th Percentile | 53.3% |
| Max | 8 269.1% |
Other Profitability Ratios
Vanta Bioscience Ltd
Glance View
Vanta Bioscience Ltd. engages in the full service preclinical contract research organization. The company is headquartered in Secunderabad, Telangana. The company went IPO on 2017-10-06. The firm is engaged in research and development in the field of discovery and development of drugs, biological, vaccines, gene-based therapies, as well as diagnostics and cosmetics, including clinical research. The company provides risk assessment services for evaluating the safety of the active pharmaceutical ingredients (API), excipients, extractable and leachable, including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. The company also provides expert services for determination of health-based exposure limits, such as permitted daily exposure (PDE) or allowable daily exposure (ADE), including occupational exposure limits (OEL) for pharmaceutical manufacturers. The firm's subsidiaries include Vanta Clinical Research Limited and Vayam Research Solutions Limited.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Vanta Bioscience Ltd is -20.2%, which is below its 3-year median of 67.5%.
Over the last 3 years, Vanta Bioscience Ltd’s Gross Margin has decreased from 92.2% to -20.2%. During this period, it reached a low of -20.2% on Sep 30, 2025 and a high of 129.7% on Sep 30, 2024.
